Dr. Hatem Soliman, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 88
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME92287
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Ability Health Services and Rehabilitation LP (1,269 clinicians)
- Ability Health Services, Inc (1,258 clinicians)
- H Lee Moffitt Cancer Ctr and Res Inst Life Time Cancer Scrn Ctr Inc (1,178 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 88
- Services billed
- 177
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 147 | 79 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Tampa, FL | 83 |
| Anastrozole Other prescribers in Tampa, FL | 46 |
| Tamoxifen Citrate Other prescribers in Tampa, FL | 25 |
| Exemestane | 23 |
| Gabapentin Other prescribers in Tampa, FL | 21 |
| Kisqali (ribociclib succinate) | 15 |
| Eliquis (apixaban) Other prescribers in Tampa, FL | 14 |
| Prochlorperazine Maleate Other prescribers in Tampa, FL | 11 |
| Tukysa (tucatinib) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 20 payments worth $14,894 in total to this clinician.
| Genentech USA, Inc. | $3,253 |
|---|---|
| Novartis Pharmaceuticals Corporation | $2,800 |
| Daiichi Sankyo Inc. | $2,490 |
| Gilead Sciences, Inc. | $2,481 |
| AstraZeneca Pharmaceuticals LP | $2,129 |
| Tersera Therapeutics LLC | $1,369 |
| Lilly USA, LLC | $229 |
| Stemline Therapeutics Inc. | $142 |
| Consulting Fee | $13,550 |
|---|---|
| Food and Beverage | $979 |
| Travel and Lodging | $365 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Nov 21, 2025 | Consulting Fee KISQALI · Oncology | $2,800 |
| Genentech USA, Inc. Dec 8, 2025 | Consulting Fee | $2,731 |
| Daiichi Sankyo Inc. Nov 12, 2025 | Consulting Fee Enhertu · ONCOLOGY | $2,460 |
| Gilead Sciences, Inc. Jun 12, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4147093;VEM US;10527804 | $2,180 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Consulting Fee | $2,010 |
| Tersera Therapeutics LLC Sep 2, 2025 | Consulting Fee Margenza · Oncology | $419 |
| Genentech USA, Inc. Dec 8, 2025 | Travel and Lodging travel to San Antonio, TX · in-kind | $365 |
| Tersera Therapeutics LLC Sep 27, 2025 | Consulting Fee Margenza · Oncology | $328 |
| Tersera Therapeutics LLC Sep 2, 2025 | Consulting Fee Margenza · Oncology | $321 |
| Tersera Therapeutics LLC Sep 2, 2025 | Consulting Fee Margenza · Oncology | $301 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $133,542 in research payments for these studies, mostly to the institutions running them.
- ALI-1201
Puma Biotechnology, Inc. - Randomized doubleblind phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine TDM1 for subjects with unresectable locallyadvanced or metastatic HER2 breast cancer HER2CLIMB02
Pfizer Inc. - A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT02107703 - A phase 2 basket study of tucatinib in combination with trastuzumab in subjects with previously treated locallyadvanced unresectable or metastatic solid tumors driven by HER2 alterations
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.